New cocktail of drugs and targeted procedure aims to control liver cancer

NCT ID NCT04472767

Recruiting now Disease control Sponsor: University of California, Irvine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This phase 2 trial is testing a combination of three drugs (cabozantinib, ipilimumab, and nivolumab) plus a procedure called TACE in 35 people with liver cancer that cannot be cured by surgery or transplant. The goal is to see if this approach can stop the cancer from growing for at least 6 months. Participants will receive the drugs and up to 3 TACE sessions over several weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cabozantinib, ipilimumab, nivolumab, and transarterial chemoembolization (TACE)
What this could lead to: If successful, this combination could offer a new treatment option to control liver cancer and extend life for patients who cannot have surgery or a transplant.
What could go wrong: This is an early phase 2 trial with only 35 participants, so results may not apply to everyone. The combination of drugs and TACE can cause serious side effects, and it is not yet known if it works better than standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC HEPATOCELLULAR CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Chao Family Comprehensive Cancer Center, University of California, Irvine
RECRUITING

Orange, California, 92868, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.